SMAD2 and cirrhosis of liver: Moreover, IL-35 might suppress the activation of the TGF-β1/Smad2/3 signaling pathway and inhibit the differentiation of Th17 cells in HBV-related liver cirrhosis patients, thereby suppressing inflammation, apoptosis, and fibrosis [26,27,28].